Bone Biologics Corp. (NASDAQ:BBLG) Short Interest Update

Bone Biologics Corp. (NASDAQ:BBLG) was the recipient of a large decline in short interest in the month of August. As of August 31st, there was short interest totaling 36,999 shares, a decline of 76.4% from the August 15th total of 156,590 shares. Based on an average daily volume of 89,427 shares, the short-interest ratio is presently 0.4 days. Currently, 1.4% of the company’s shares are short sold.

Bone Biologics Stock Performance

BBLG stock traded down $0.01 during trading on Friday, reaching $0.55. The company had a trading volume of 11,288 shares, compared to its average volume of 72,418. The company has a market cap of $1.52 million, a price-to-earnings ratio of -0.40 and a beta of 0.89. Bone Biologics has a twelve month low of $0.54 and a twelve month high of $2.89. The firm has a 50-day simple moving average of $0.87 and a 200-day simple moving average of $1.13.

Bone Biologics (NASDAQ:BBLG) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Sell-side analysts expect that Bone Biologics will post -1.23 earnings per share for the current year.

Hedge Funds Weigh In On Bone Biologics

A hedge fund recently raised its position in Bone Biologics stock. DRW Securities LLC raised its stake in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 23,576 shares of the company’s stock after buying an additional 12,549 shares during the quarter. DRW Securities LLC owned about 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Institutional investors own 34.30% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Bone Biologics in a research report on Friday, July 24th. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the stock currently has an average rating of “Sell”.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.